Your session is about to expire
← Back to Search
NBI-1070770: Low Dose for Depression
Study Summary
"This trial will test whether a new medication, NBI-1070770, is better than a placebo at reducing symptoms of depression in people with major depressive disorder."
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current enrollment size of participants for this research?
"Indeed, the details on clinicaltrials.gov highlight the ongoing recruitment process for this trial. The study was initially posted on March 1st, 2024 and most recently updated on March 8th, 2024. A total of 72 participants are sought from two designated sites."
Are individuals aged 55 and older eligible to participate in this trial?
"The trial is seeking individuals over 18 years of age but under the age of 65 to enroll as participants."
What level of risk does the medium dose of NBI-1070770 pose to patients?
"Our team at Power rated the safety of NBI-1070770: Medium Dose as 2 on a scale from 1 to 3. This rating is due to its Phase 2 trial status, indicating some evidence supporting safety but lacking data confirming efficacy."
Are new participants currently being accepted for this research study?
"Affirmative. Evidence from clinicaltrials.gov indicates that this study is currently seeking participants. The trial was initially published on March 1, 2024, and last revised on March 8, 2024. Researchers aim to enroll a total of 72 patients distributed across two designated centers."
Which demographic is considered the most suitable for inclusion in this medical study?
"This research is open to enrolling 72 individuals aged between 18 and 65 who are grappling with depression. Specifically, applicants must present a primary diagnosis of either recurrent MDD or persistent MDD. Of significant importance, candidates currently undergoing pharmacological therapy for their depressive symptoms should have maintained this treatment regimen for no less than eight weeks before the screening process and express readiness to persist with the current antidepressant medication protocol. Moreover, potential participants need to demonstrate willingness and capability in adhering to all outlined study protocols and limitations."
Share this study with friends
Copy Link
Messenger